Semaxanib clinical trial progress and patents: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma	National Cancer Institute (NCI)	Phase 1/Phase 2
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma	Radiation Therapy Oncology Group	Phase 1/Phase 2
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma	National Cancer Institute (NCI)	Phase 1/Phase 2

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: September 8, 2026

Semaxanib, also known as SU5416, is an investigational small-molecule VEGFR2 inhibitor that was abandoned after disappointing clinical results. Its development was led by SUGEN, later acquired by Pharmacia and Pfizer. Semaxanib never received FDA approval, has no Orange Book-listed product, and has no established commercial market. Its current value is limited to academic research, historical oncology analysis, and possible use as a reference compound in angiogenesis research.

What is the current development status of semaxanib?

Semaxanib is not an active late-stage drug-development program. Clinical development ended after efficacy results failed to support further investment, particularly in advanced colorectal cancer. No approved formulation, commercial dosage form, or active regulatory program has emerged.

Field	Semaxanib status
Generic name	Semaxanib
Development code	SU5416
Primary sponsor	SUGEN
Subsequent corporate owner	Pharmacia, later Pfizer
Drug class	Small-molecule receptor tyrosine kinase inhibitor
Main target	VEGFR2, also called KDR
Regulatory status	Never approved
FDA application	No approved NDA identified
Orange Book status	No listed product
Commercial availability	Not marketed as a medicine
Development status	Discontinued
Current market	Research use and historical scientific interest

Semaxanib was designed to block VEGF-mediated signaling through VEGFR2, a pathway involved in tumor angiogenesis. The compound showed antiangiogenic activity in preclinical models and entered human studies during the first wave of targeted angiogenesis therapies.[1][2]

How does semaxanib work?

Semaxanib inhibits VEGFR2/KDR signaling by binding to the kinase domain of the receptor. VEGFR2 activation promotes endothelial-cell proliferation, migration, vascular permeability, and new blood-vessel formation. Blocking this pathway was expected to restrict tumor vascularization.

The mechanism had a strong biological rationale, but clinical activity depended on more than VEGFR2 inhibition. Tumor biology, alternative angiogenic pathways, pharmacokinetic exposure, dose tolerability, and disease-specific resistance limited the compound’s therapeutic performance.

Semaxanib was an early-generation VEGFR inhibitor. Compared with later agents such as sorafenib, sunitinib, pazopanib, and axitinib, it had a narrower development record and did not establish a durable clinical benefit in a major cancer indication.

Which clinical indications were studied for semaxanib?

Semaxanib was evaluated across several oncology settings, including:

Advanced colorectal cancer
Non-small-cell lung cancer
Renal-cell carcinoma
Glioblastoma and other high-grade gliomas
Acute myeloid leukemia
Kaposi sarcoma
Other refractory solid tumors

The most commercially important program involved advanced colorectal cancer, where semaxanib was studied with chemotherapy regimens including 5-fluorouracil and leucovorin. The program did not produce results sufficient to support registration.

Early studies reported signs of biological or antitumor activity, but these findings did not translate into a clinically viable benefit-risk profile in larger development programs.[2][3]

When was semaxanib development discontinued?

Development was effectively discontinued in the early 2000s after negative or inconclusive results in advanced cancer studies. The program was no longer positioned as a registration-stage asset after failure to demonstrate sufficient benefit in colorectal cancer.

Semaxanib development timeline

Period	Event
1990s	SUGEN develops SU5416 as a selective VEGFR2/KDR inhibitor
Late 1990s	First-in-human and early phase oncology studies begin
1999-2001	Phase I and Phase II studies evaluate refractory solid tumors and hematologic cancers
2001-2002	Combination studies assess semaxanib with chemotherapy in advanced colorectal cancer
Early 2000s	Larger studies fail to establish adequate clinical efficacy
2002-2003	Commercial development is discontinued
Since discontinuation	No FDA approval, commercial launch, or active late-stage program

Published records vary in how they describe the exact timing of program termination because individual trials closed at different dates. The commercial conclusion is consistent: semaxanib did not progress to approval.

What were the main reasons semaxanib failed clinically?

The principal issue was inadequate clinical efficacy relative to the development standard and treatment burden. Antiangiogenic activity alone did not produce a sufficiently durable response in the tested populations.

Potential contributors included:

Limited potency and exposure compared with later VEGFR inhibitors.
Tumor adaptation through alternative proangiogenic pathways.
Heterogeneity among VEGFR-dependent tumors.
Difficulty combining the drug with cytotoxic chemotherapy.
Toxicity associated with vascular pathway inhibition.
Lack of a validated biomarker for patient selection.

Semaxanib also illustrates the distinction between target validation and compound validation. VEGFR2 proved to be a clinically relevant target, but that did not establish semaxanib as a successful drug. Later agents targeting VEGFR signaling achieved approvals in renal-cell carcinoma, hepatocellular carcinoma, thyroid cancer, and other settings using different selectivity, pharmacokinetic, and combination strategies.

What is the FDA regulatory status of semaxanib?

Semaxanib has no FDA approval and no current regulatory pathway toward approval.

There is no evidence of:

An approved New Drug Application
An FDA-approved indication
A licensed commercial sponsor
An FDA-approved dosage form
A current breakthrough, fast-track, orphan, or priority-review designation
A biosimilar or generic application

Because semaxanib was never approved, it has no FDA-recognized exclusivity period. It also has no regulatory reference product against which an Abbreviated New Drug Application could be filed.

What is the Orange Book status of semaxanib?

Semaxanib has no known Orange Book listing. The Orange Book lists approved drug products and associated patents or regulatory exclusivities. An investigational compound that never reached approval normally does not appear as an approved reference listed drug.

Orange Book issue	Semaxanib status
Reference listed drug	None
Approved NDA	None
Listed patent	None associated with an approved product
Listed method-of-use patent	None
Paragraph IV exposure	None in the normal ANDA context
Pediatric exclusivity	None
New chemical entity exclusivity	Not granted because approval did not occur

What patents protect semaxanib?

Historical patent protection likely covered the compound, related chemical entities, pharmaceutical compositions, and methods of inhibiting VEGFR-mediated angiogenesis. SUGEN was the principal originator associated with SU5416 and related kinase-inhibitor research.

A current commercial patent estate is not material because:

The compound was discovered more than two decades ago.
Any original small-molecule composition-of-matter patents would generally have expired or be close to expiration.
Semaxanib was never commercialized through an approved product.
No active Orange Book patent position exists.
No current sponsor has disclosed a modern reformulation or development strategy.

The historical patent estate should not be confused with an active exclusivity position. Patent families may include national filings, continuations, divisionals, and improvement claims, but those rights do not create practical market protection without a viable clinical and regulatory program.

Patent and exclusivity assessment

Protection category	Commercial assessment
Composition of matter	Historical protection; likely expired or commercially immaterial
Pharmaceutical composition	Historical protection; no approved product linkage
Method of treatment	Potentially relevant historically; no active marketed indication
Manufacturing process	No identified current barrier to commercial development
Formulation	No established marketed formulation
Regulatory exclusivity	None
Orphan-drug exclusivity	None identified
Patent-term extension	Not applicable to an approved product
Freedom to develop	Requires a current jurisdiction-by-jurisdiction search

A definitive live-patent opinion would require a formal global family and prosecution review. The practical conclusion is clearer: semaxanib has no active patent position supporting a commercial product in the United States.

Could semaxanib face Paragraph IV challenges or generic entry?

Traditional Paragraph IV litigation is not a meaningful issue because semaxanib has no approved reference listed drug. An ANDA applicant cannot rely on semaxanib as an approved reference product in the usual Hatch-Waxman pathway.

Any future developer would likely pursue one of the following routes:

A full 505(b)(1) NDA supported by original clinical data.
A 505(b)(2) application if an approved reference or bridgeable data package became relevant.
A research or diagnostic-use product outside the prescription-drug market.
A repurposing program supported by new clinical evidence.

The principal barrier is therefore clinical and regulatory validation, not patent exclusivity.

What formulations are protected by semaxanib patents?

No commercially established semaxanib formulation exists. Clinical studies used investigational formulations, but those formulations did not become approved dosage forms.

There is no recognized market product for:

Oral semaxanib tablets
Semaxanib capsules
Injectable semaxanib
Sustained-release semaxanib
Liposomal semaxanib
Combination semaxanib products

A new formulation could theoretically support separate patent claims if it delivered a meaningful pharmacokinetic, stability, safety, or efficacy improvement. Such a strategy would require new clinical work and would not restore the original asset’s commercial value by itself.

What patent litigation or settlement agreements affect semaxanib?

No material current patent litigation or Hatch-Waxman settlement involving semaxanib is publicly associated with an approved product. No established generic launch settlement, authorized generic arrangement, or biosimilar settlement is relevant.

The absence of litigation reflects the drug’s development history. Semaxanib was discontinued before an approved product generated the patent disputes typically seen in oncology medicines.

Does semaxanib have biosimilar risk?

No. Semaxanib is a synthetic small molecule, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply.

The relevant competitive risk would be from:

New VEGFR2 inhibitors
Multikinase inhibitors
Anti-VEGF antibodies
Antibody-drug conjugates
Immunotherapy combinations
New antiangiogenic agents with better selectivity or tolerability

Semaxanib’s competitive position is weak because the oncology market has advanced substantially since its clinical development ended.

How does semaxanib compare with approved VEGFR inhibitors?

Drug	Main target profile	Approval status	Commercial position
Semaxanib	Primarily VEGFR2/KDR	Never approved	No commercial market
Sunitinib	VEGFR, PDGFR, KIT and others	Approved	Established oncology product
Sorafenib	VEGFR, PDGFR, RAF and others	Approved	Established oncology product
Pazopanib	VEGFR, PDGFR, FGFR and others	Approved	Renal-cell and soft-tissue sarcoma use
Axitinib	Relatively selective VEGFR1-3	Approved	Renal-cell carcinoma use
Cabozantinib	VEGFR, MET, AXL and others	Approved	Multiple oncology indications
Bevacizumab	VEGF-A antibody	Approved	Broad antiangiogenic franchise

Semaxanib helped establish the scientific rationale for VEGFR-directed therapy but did not compete successfully with later products. Its lack of approval, limited clinical differentiation, and discontinued sponsor support leave it without a credible commercial recovery path.

What is the commercial market projection for semaxanib?

The forecast prescription-drug market for semaxanib is effectively zero unless a new sponsor restarts development and generates positive clinical data. There is no approved product revenue, no reimbursed treatment market, and no established prescriber base.

Market segment	Near-term projection
FDA-approved prescription sales	$0
European approved prescription sales	$0
Generic prescription sales	$0
Biosimilar sales	Not applicable
Research-use compound sales	Limited and non-comparable
Licensing value as a standalone drug	Low
Value as a mechanistic research tool	Modest

Any commercial value would depend on a major repositioning, such as a biomarker-defined cancer subgroup, a new delivery system, or a combination regimen. That scenario would require renewed toxicology, manufacturing, clinical, and regulatory investment. It cannot be supported by the historical development record alone.

What generic launch risks exist for semaxanib?

Generic-launch risk is low because there is no approved innovator product to displace. The more relevant risk for a new semaxanib developer would be competition from existing approved VEGFR inhibitors and off-patent oncology medicines.

A hypothetical relaunch would face:

Clinical-development failure risk
Strong competition from approved VEGFR inhibitors
Reimbursement and guideline-adoption barriers
Potential toxicity-related discontinuation
Lack of a validated predictive biomarker
Manufacturing and formulation redevelopment costs
Possible prior-art challenges against new patent claims

The absence of blocking exclusivity could reduce legal entry barriers, but it does not create an attractive market. In this case, the commercial problem is demand generation and clinical differentiation.

What licensing deals affected semaxanib?

SUGEN’s corporate relationships and eventual acquisition history were more important than a continuing standalone licensing model. SUGEN was acquired by Pharmacia, which later became part of Pfizer. The transaction transferred relevant discovery programs and intellectual property, but semaxanib itself did not become a marketed Pfizer oncology product.

No current licensing transaction gives semaxanib a meaningful commercial valuation. Any historical rights would need to be assessed against patent expiration, termination provisions, surviving know-how rights, and corporate ownership records.

What are the manufacturing and intellectual-property barriers?

Manufacturing semaxanib as a research compound is likely less difficult than developing it as a prescription product. A commercial program would require:

Current Good Manufacturing Practice production
Validated impurity controls
Stable drug substance and drug product specifications
Clinical-grade formulation
Reproducible analytical methods
Updated nonclinical safety documentation
A new clinical development plan

Intellectual-property barriers appear weaker than scientific and regulatory barriers. New formulation or combination patents might be possible, but broad protection around the original molecule would face substantial prior-art and expiration concerns.

Which companies are challenging semaxanib?

No company is known to be actively challenging semaxanib through a current generic, biosimilar, or patent-litigation program. Competitive pressure comes indirectly from developers and manufacturers of approved antiangiogenic therapies, including Pfizer, Bayer, Novartis, Exelixis, and Roche.

Those companies compete in the same broad therapeutic area, but they are not semaxanib challengers in the Hatch-Waxman sense.

What is the investment outlook for semaxanib?

Semaxanib has low standalone investment attractiveness. The asset has no approval, no revenue, no active clinical program, and no meaningful exclusivity runway.

Potential value is confined to:

Academic angiogenesis research
Comparative kinase pharmacology
Historical oncology drug-development analysis
Use as a laboratory reference compound
Possible hypothesis generation for biomarker-driven repurposing

A financing thesis based solely on historical VEGFR2 activity would be weak. A credible investment case would require new data showing a differentiated safety or efficacy profile against modern VEGFR inhibitors.

Key Takeaways

Semaxanib, or SU5416, is a discontinued investigational VEGFR2 inhibitor.
SUGEN originated the program; Pharmacia and Pfizer later controlled related development assets.
The drug was studied in colorectal cancer, lung cancer, renal-cell carcinoma, glioblastoma, leukemia, and other cancers.
Clinical development ended in the early 2000s after inadequate efficacy and an unfavorable commercial outlook.
Semaxanib has no FDA approval, Orange Book listing, regulatory exclusivity, or marketed formulation.
Paragraph IV litigation and biosimilar competition are not relevant.
Historical patent rights are unlikely to provide meaningful current market protection.
Prescription revenue is effectively zero without a completely new development program.
The main barriers are clinical validation, differentiation, reimbursement, and competition from approved VEGFR therapies.

FAQs About Semaxanib

Is semaxanib still in clinical trials?

No active late-stage development program is established. Historical clinical studies have ended, and the compound is not an FDA-approved therapy.

Can semaxanib be prescribed for cancer treatment?

No. Semaxanib is not an approved cancer treatment and is not available as a standard prescription medicine.

Is semaxanib the same as sunitinib?

No. Both compounds affect VEGFR signaling, but semaxanib is an investigational VEGFR2 inhibitor, while sunitinib is an approved multikinase inhibitor with distinct pharmacology and clinical indications.

Could semaxanib be repurposed for a new cancer indication?

In principle, a sponsor could restart development, but repurposing would require new clinical evidence, updated manufacturing, regulatory engagement, and a differentiated treatment hypothesis.

What is the present research value of semaxanib?

Its main value is as a historical and experimental VEGFR2 inhibitor used in angiogenesis research, kinase biology, and comparative studies of antiangiogenic mechanisms.

References

Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Rishton, G., Flanagan, E., Lu, Y., Tang, C., Sun, J., Iyer, V., Bollag, G., Manley, P. W., McMahon, G., & Hirth, K. P. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Research, 59(1), 99-106.
Klohs, W. D., & Hamby, J. M. (1999). Antiangiogenic agents. Current Opinion in Biotechnology, 10(6), 544-549.
National Cancer Institute. (n.d.). Semaxanib (SU5416) clinical development information. National Institutes of Health.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
ClinicalTrials.gov. (n.d.). Studies involving SU5416 and semaxanib. U.S. National Library of Medicine.
Pharmacia Corporation. (2002). Annual report and pharmaceutical development disclosures. Pharmacia Corporation.

US Patents	0
International Patents	0
US Patent Applications	5,280
WIPO Patent Applications	1,595
Japanese Patent Applications	467
Clinical Trial Progress	Phase 3 (2000-12-01)
Vendors	54

Investigational Drug Information for Semaxanib

What is the development status for investigational drug Semaxanib?

Summary for Semaxanib

Recent Clinical Trials for Semaxanib

Clinical Trial Summary for Semaxanib

Top disease conditions for Semaxanib

Top clinical trial sponsors for Semaxanib

US Patents for Semaxanib

Semaxanib Development Update, Patent Status, and Market Projection